
Home » CELTIC PHARMA STARTS TA-NIC TRIAL
CELTIC PHARMA STARTS TA-NIC TRIAL
Celtic Pharmaceutical has announced that approval has been granted in the UK to start a Phase II trial of TA-NIC, a vaccine being developed for the treatment of nicotine addiction. The trial is a placebo controlled, multicenter study, designed to assess the efficacy and safety of TA-NIC in maintaining smoking cessation when given in conjunction with current standard support treatments.
TA-NIC is a therapeutic vaccine in development for the treatment of nicotine addiction. Anti-nicotine antibodies, which the vaccine is designed to raise, bind to nicotine in the bloodstream. Since antibodies are too large to cross the blood-brain barrier, bound nicotine should be prevented from getting to the brain. Consequently, the pleasurable stimulus which usually accompanies smoking should be absent or reduced.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct